Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

May 29, 2014

Drug R&D: Big Data for Big Returns

More ROI from research and development is urgently needed.

Drug R&D: Big Data for Big Returns

Both access to big data and fully realizing success from its use require the right relationships within the greater healthcare/life sciences ecosystem. [© kentoh - Fotolia.com]

  • Cost pressures and new pay-for-performance payer approaches are making demonstration of real-world outcomes as essential to the drug research and development (R&D) model as ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »